NASDAQ-GS · traded in Congress
Gilead Sciences, GILD
$170.25 +3.36 (+2.01%) Nov 9, 2026 4:22 AM ET
Market value$211.2B
P/E ratio-
Analyst target$175.00
52-week range-
Avg volume6,013,016
Dividend yield1.96%
Chart
Analyst ratings
- 23 buy
- 6 hold
- 1 sell
Low target$131.00
Average target$175.12
High target$200.00
Quarterly financials
| Quarter ended | Revenue | Gross profit | Net income | Net margin |
|---|---|---|---|---|
| $8,300M | - | $2,429M | 29.3% | |
| $7,803M | - | $-10,496M | -134.5% | |
| $6,960M | - | $2,021M | 29.0% | |
| $7,925M | - | $2,183M | 27.6% |
Congress trades in GILD
Members of Congress disclosed 2 transactions in GILD in the filings we have processed.
| Traded | Member | Type | Amount | Filed |
|---|---|---|---|---|
| 05/06/2026 | Jared Moskowitz FL23 | Purchase | $1,001 - $15,000 | 6/19/2026 filing |
| 05/06/2026 | Jared Moskowitz FL23 | Purchase | $1,001 - $15,000 | 6/19/2026 filing |
Disclosed under the STOCK Act. Amounts are the ranges the law requires, filings can lag a trade by up to 45 days, and a disclosure is not evidence of wrongdoing. All congressional trades ›
Other companies
Price and key figures from Nasdaq's public quote data, refreshed through the day; the chart is live from TradingView; options activity, ratings, financials, earnings and filings refreshed through the day. Congressional trades parsed from official House filings. Market information, not investment advice.
